AlphaMaven AlphaMaven

Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics

Reported by Business Wire
Nov 16, 2026· 2 min read
Save Post LinkedIn Email
Key Takeaways
  • • Seawolf Therapeutics emerged from stealth with $100 million in financing to advance its LNP-based DNA delivery platform, TRIDENT, according to a Business Wire announcement.
  • • Series A investors include Versant Ventures, MPM BioImpact, Novartis Venture Fund, Eli Lilly and Company, and CRISPR Therapeutics AG, with Versant having led the seed round.
  • • A multi-target research collaboration and exclusive license with Sanofi carries up to $1.2 billion in research, development and commercial milestones, plus tiered royalties.
  • • Seawolf reports sustained protein expression above therapeutic levels in primates at safe, well-tolerated doses, and its lead metabolic disease program is advancing to Development Candidate.
Summary
Seawolf Therapeutics, a privately held biotechnology company headquartered in San Diego, announced its emergence from stealth after raising $100 million to develop therapies based on its proprietary lipid nanoparticle (LNP)-based DNA delivery platform. Versant Ventures led the seed round. The Series A financing was led by Versant alongside MPM BioImpact and Novartis Venture Fund (NVF), with participation from Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments, and Pathway to Cures, the philanthropic venture arm of the National Bleeding Disorders Foundation, among others.

The company also disclosed a multi-target research collaboration and exclusive license agreement with Sanofi to develop undisclosed therapies for bleeding disorders and additional unnamed indications. The agreement carries up to $1.2 billion in research, development and commercial milestones, as well as tiered royalties on any resulting product sales.

The funds will advance Seawolf's TRIDENT (Targeted RNA-Induced DNA Expression via Nuclear Translocation) platform. According to the company, TRIDENT pairs the potency, redosability, safety and scalability of RNA-based LNP therapies with durable expression, which RNA approaches lack, by delivering DNA-based payloads. The system uses a proprietary LNP carrying an immune-quiet DNA that encodes a therapeutic transgene, along with an auxiliary factor that facilitates nuclear access. Seawolf states that, unlike virus-based DNA platforms, TRIDENT therapies are redosable, allowing dose adjustment through repeat administration.

Seawolf reports sustained protein expression above therapeutic levels in primates at safe, well-tolerated doses and proof-of-concept in primate and murine preclinical models of metabolic and rare diseases. The platform may be applied to replacing mutant genes and expressing biologics systemically. The company's lead proprietary program, targeting metabolic diseases, is advancing to Development Candidate status. CEO Elizabeth Alcamo, Ph.D., said the company is positioned to advance that program and collaborate with Sanofi. Tom Woiwode, Ph.D., managing director at Versant and chair of Seawolf's board, said the technology aims to drive robust, long-term expression of therapeutic proteins from patients' own cells.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Business Wire Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics